Cargando…
Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand
PURPOSE: To investigate the medium-term clinical outcomes and risk factors for primary graft failure after Descemet membrane endothelial keratoplasty (DMEK) in Thai patients. PATIENTS AND METHODS: This is a single-center retrospective cohort study. Sixty-two eyes of 62 patients who underwent DMEK at...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180280/ https://www.ncbi.nlm.nih.gov/pubmed/34103888 http://dx.doi.org/10.2147/OPTH.S310873 |
_version_ | 1783703968309837824 |
---|---|
author | Lekhanont, Kaevalin Pisitpayat, Punyanuch Cheewaruangroj, Nontawat Jongkhajornpong, Passara Nonpassopon, Manachai Anothaisintawee, Thunyarat |
author_facet | Lekhanont, Kaevalin Pisitpayat, Punyanuch Cheewaruangroj, Nontawat Jongkhajornpong, Passara Nonpassopon, Manachai Anothaisintawee, Thunyarat |
author_sort | Lekhanont, Kaevalin |
collection | PubMed |
description | PURPOSE: To investigate the medium-term clinical outcomes and risk factors for primary graft failure after Descemet membrane endothelial keratoplasty (DMEK) in Thai patients. PATIENTS AND METHODS: This is a single-center retrospective cohort study. Sixty-two eyes of 62 patients who underwent DMEK at Ramathibodi Hospital, Bangkok, Thailand, with a minimum of 24-month follow-up were recruited. Preoperative donor and recipient characteristics, intraoperative data, and postoperative outcomes including best-corrected visual acuity (BCVA), graft clarity, endothelial cell density (ECD), central corneal thickness (CCT), and complications were evaluated at 1, 3, 6, 12, and 24 months after surgery. RESULTS: The mean age of the patients was 67.2 ± 9.9 years, and 52% were female. The mean follow-up time was 37.5 ± 11.0 months. The most common indications for DMEK were Fuchs’ endothelial corneal dystrophy (FECD) (53.2%) and pseudophakic bullous keratopathy (PBK) (17.7%). Nearly half of patients had triple-DMEK. The median preoperative BCVA was 20/400. Postoperative BCVA of ≥ 20/40 was reached in 37.1% and of ≥ 20/20 in 6.5% after 1 month which increased to 54.8% and 17.7% after 3 months; and to 67.7% and 27.4% after 24 months. Endothelial cell loss (ECL) at 3, 6, 12, and 24 months was 30.5%, 33.8%, 44.4%, and 45.9%, respectively. Graft diameter was the single factor, showing a significant relationship with postoperative ECD. Most frequent postoperative complications included graft detachment (22.6%), increased IOP/glaucoma (17.7%), and primary graft failure (16.1%). In univariate analysis, death-to-operation time and the diagnosis of PBK were significantly associated with the occurrence of primary graft failure. CONCLUSION: DMEK is a safe, effective, and feasible treatment for endothelial failure in Asian eyes. Careful case selection, use of relatively fresh donor tissues, and appropriate surgical techniques can prevent primary graft failure and facilitate optimal outcomes following surgery. |
format | Online Article Text |
id | pubmed-8180280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-81802802021-06-07 Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand Lekhanont, Kaevalin Pisitpayat, Punyanuch Cheewaruangroj, Nontawat Jongkhajornpong, Passara Nonpassopon, Manachai Anothaisintawee, Thunyarat Clin Ophthalmol Original Research PURPOSE: To investigate the medium-term clinical outcomes and risk factors for primary graft failure after Descemet membrane endothelial keratoplasty (DMEK) in Thai patients. PATIENTS AND METHODS: This is a single-center retrospective cohort study. Sixty-two eyes of 62 patients who underwent DMEK at Ramathibodi Hospital, Bangkok, Thailand, with a minimum of 24-month follow-up were recruited. Preoperative donor and recipient characteristics, intraoperative data, and postoperative outcomes including best-corrected visual acuity (BCVA), graft clarity, endothelial cell density (ECD), central corneal thickness (CCT), and complications were evaluated at 1, 3, 6, 12, and 24 months after surgery. RESULTS: The mean age of the patients was 67.2 ± 9.9 years, and 52% were female. The mean follow-up time was 37.5 ± 11.0 months. The most common indications for DMEK were Fuchs’ endothelial corneal dystrophy (FECD) (53.2%) and pseudophakic bullous keratopathy (PBK) (17.7%). Nearly half of patients had triple-DMEK. The median preoperative BCVA was 20/400. Postoperative BCVA of ≥ 20/40 was reached in 37.1% and of ≥ 20/20 in 6.5% after 1 month which increased to 54.8% and 17.7% after 3 months; and to 67.7% and 27.4% after 24 months. Endothelial cell loss (ECL) at 3, 6, 12, and 24 months was 30.5%, 33.8%, 44.4%, and 45.9%, respectively. Graft diameter was the single factor, showing a significant relationship with postoperative ECD. Most frequent postoperative complications included graft detachment (22.6%), increased IOP/glaucoma (17.7%), and primary graft failure (16.1%). In univariate analysis, death-to-operation time and the diagnosis of PBK were significantly associated with the occurrence of primary graft failure. CONCLUSION: DMEK is a safe, effective, and feasible treatment for endothelial failure in Asian eyes. Careful case selection, use of relatively fresh donor tissues, and appropriate surgical techniques can prevent primary graft failure and facilitate optimal outcomes following surgery. Dove 2021-05-31 /pmc/articles/PMC8180280/ /pubmed/34103888 http://dx.doi.org/10.2147/OPTH.S310873 Text en © 2021 Lekhanont et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lekhanont, Kaevalin Pisitpayat, Punyanuch Cheewaruangroj, Nontawat Jongkhajornpong, Passara Nonpassopon, Manachai Anothaisintawee, Thunyarat Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand |
title | Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand |
title_full | Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand |
title_fullStr | Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand |
title_full_unstemmed | Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand |
title_short | Outcomes of Descemet Membrane Endothelial Keratoplasty in Bangkok, Thailand |
title_sort | outcomes of descemet membrane endothelial keratoplasty in bangkok, thailand |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180280/ https://www.ncbi.nlm.nih.gov/pubmed/34103888 http://dx.doi.org/10.2147/OPTH.S310873 |
work_keys_str_mv | AT lekhanontkaevalin outcomesofdescemetmembraneendothelialkeratoplastyinbangkokthailand AT pisitpayatpunyanuch outcomesofdescemetmembraneendothelialkeratoplastyinbangkokthailand AT cheewaruangrojnontawat outcomesofdescemetmembraneendothelialkeratoplastyinbangkokthailand AT jongkhajornpongpassara outcomesofdescemetmembraneendothelialkeratoplastyinbangkokthailand AT nonpassoponmanachai outcomesofdescemetmembraneendothelialkeratoplastyinbangkokthailand AT anothaisintaweethunyarat outcomesofdescemetmembraneendothelialkeratoplastyinbangkokthailand |